Welcome to the Canadian National Multilingual News Group (CNMNG). This is a project made possible through funding by Canadian Heritage. CNMNG aims to gather news researched and written by a corps of Canadian-based journalists/writers from the country’s multilingual community groups. The overall goal is to inform, analyze and critique the issues of the day in a professional manner and to provide that to publishers and editors active in the ethnocultural-multilingual press and media whose experience provides them with a perspective that is sensitive to news relevant to their own language group.
[GTranslate]ROME – The Embassy of Canada in Italy has issued the call for the ninth edition of the Canada-Italy Award for Innovation 2021, aimed at promoting projects to build new ways of living and working together, in order to adapt and mitigate the impacts of COVID-19. The opportunity is offered to projects in every sector, from research to information. →
[gtranslate]TORONTO – The Covid-19 pandemic response may have some unexpected effects, for instance, a reduction in the prevalence of influenza. Yet, it has exacerbated a dark and deadly issue, the opioid crisis in Canada. Communities across the nation are reeling from the unprecedented levels of drug-related deaths.
Canadá supera los 800 mil casos de Covid-19, pero en el Atlántico la situación está controlada
El mundo continúa decretando nuevos cierres, políticas y confinamientos para contener el rebrote de Covid-19, mientras que la burbuja con la que se protege el Atlántico canadiense parece surtir efecto. Incluso cuando el resto de Canadá ha cruzado otro desalentador umbral con más de 800 mil casos, la región atlántica continúa su ritmo de vida. →
[GTranslate]Pfizer and Moderna have started testing their vaccines on children from 12 years of age and hope to have the results of the trial by the summer: according to New York Times (read here: Covid Vaccines for Kids Are Coming, but Not for Many Months), the two pharmaceutical companies could later start testing on children even younger. Johnson & Johnson, Novavax, and AstraZeneca also have similar projects, but they are at a less advanced stage than Pfizer and Moderna. →
